Literature DB >> 30718245

Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.

Clare L Kinnear1, Twisha S Patel2, Carol L Young3, Vincent Marshall2, Duane W Newton3, Andrew F Read4, Robert J Woods5.   

Abstract

Vancomycin-resistant Enterococcus (VRE) is a leading cause of hospital-acquired infection, with limited treatment options. Resistance to one of the few remaining drugs, daptomycin, is a growing clinical problem and has previously been described in this hospital. In response to increasing resistance, an antimicrobial stewardship intervention was implemented to reduce hospital-wide use of daptomycin. To assess the impact of the intervention, daptomycin prescribing patterns and clinically reported culture results from vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infections (BSIs) from 2011 through 2017 were retrospectively extracted and the impact of the intervention was estimated using interrupted time series analysis (ITS). We corrected for a change in MIC determination methodology by retesting 262 isolates using Etest and broth microdilution. Hospital-wide and within-patient resistance patterns of corrected daptomycin MICs are reported. Our data show that daptomycin prescriptions decreased from an average of 287 days of therapy/month preintervention to 151 days of therapy/month postintervention. Concurrently, the proportion of patients experiencing an increase in daptomycin MIC during an infection declined from 14.6% (7/48 patients) in 2014 to 1.9% (1/54 patients) in 2017. Hospital-wide resistance to daptomycin also decreased in the postintervention period, but this was not maintained. This study shows that an antimicrobial stewardship-guided intervention reduced daptomycin use and improved individual level outcomes but had only transient impact on the hospital-level trend.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Enterococcuszzm321990; antimicrobial resistance; antimicrobial stewardship; daptomycin; evolution

Mesh:

Substances:

Year:  2019        PMID: 30718245      PMCID: PMC6437541          DOI: 10.1128/AAC.01800-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

Review 1.  Management of multidrug-resistant organisms in health care settings, 2006.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

2.  Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China.

Authors:  Qin-Jing Li; Wei-Wei Jiao; Qing-Qin Yin; Fang Xu; Jie-Qiong Li; Lin Sun; Jing Xiao; Ying-Jia Li; Igor Mokrousov; Hai-Rong Huang; A-Dong Shen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests.

Authors:  Shelley A Campeau; Audrey N Schuetz; Peggy Kohner; Cesar A Arias; Peera Hemarajata; Jennifer Dien Bard; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.

Authors:  V I Enne; D M Livermore; P Stephens; L M Hall
Journal:  Lancet       Date:  2001-04-28       Impact factor: 79.321

5.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Authors:  Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

6.  Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.

Authors:  Robert J Woods; Twisha S Patel; Jerod L Nagel; Duane W Newton; Andrew F Read
Journal:  Infect Control Hosp Epidemiol       Date:  2018-01-14       Impact factor: 3.254

7.  Systematic evaluation of commercial susceptibility testing methods for determining the in vitro activity of daptomycin versus Staphylococcus aureus and Enterococci.

Authors:  Thomas J Kirn; Elizabeth Onyeaso; Madiha Syed; Melvin P Weinstein
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

8.  Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.

Authors:  Benjamin P Howden; Christopher R E McEvoy; David L Allen; Kyra Chua; Wei Gao; Paul F Harrison; Jan Bell; Geoffrey Coombs; Vicki Bennett-Wood; Jessica L Porter; Roy Robins-Browne; John K Davies; Torsten Seemann; Timothy P Stinear
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

9.  Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci.

Authors:  Scott K Fridkin; Rachel Lawton; Jonathan R Edwards; Fred C Tenover; John E McGowan; Robert P Gaynes
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

10.  Why sensitive bacteria are resistant to hospital infection control.

Authors:  Esther van Kleef; Nantasit Luangasanatip; Marc J Bonten; Ben S Cooper
Journal:  Wellcome Open Res       Date:  2017-11-22
View more
  3 in total

1.  Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium.

Authors:  Clare L Kinnear; Elsa Hansen; Valerie J Morley; Kevin C Tracy; Meghan Forstchen; Andrew F Read; Robert J Woods
Journal:  PLoS Biol       Date:  2020-12-17       Impact factor: 8.029

2.  An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.

Authors:  Valerie J Morley; Clare L Kinnear; Derek G Sim; Samantha N Olson; Lindsey M Jackson; Elsa Hansen; Grace A Usher; Scott A Showalter; Manjunath P Pai; Robert J Woods; Andrew F Read
Journal:  Elife       Date:  2020-12-01       Impact factor: 8.140

3.  Emergence of pstS-Null Vancomycin-Resistant Enterococcus faecium Clone ST1478, Canada, 2013-2018.

Authors:  Melissa McCracken; Robyn Mitchell; Stephanie Smith; Susy Hota; John Conly; Tim Du; John Embil; Lynn Johnston; Debbie Ormiston; Jennifer Parsonage; Andrew Simor; Alice Wong; George Golding
Journal:  Emerg Infect Dis       Date:  2020-09       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.